Success Metrics

Clinical Success Rate

100.0%

Based on 4 completed trials

Completion Rate

100%(4/4)

Active Trials

3(43%)

Results Posted

75%(3 trials)

Phase Distribution

Ph phase_1

14%

Ph phase_3

14%

Ph phase_2

71%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution7 total trials

Phase 1Safety & dosage

1(14.3%)

Phase 2Efficacy & side effects

5(71.4%)

Phase 3Large-scale testing

1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(4)

Detailed Status

Completed4

Active, not recruiting2

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 11 (14.3%)

Phase 25 (71.4%)

Phase 31 (14.3%)

Trials by Status

completed457%

recruiting114%

active_not_recruiting229%

Recent Activity

3 active trials

Showing 5 of 7

recruitingphase_2

A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease

NCT07203001

completedphase_2

A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)

NCT06097663

active_not_recruitingphase_2

Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations

NCT04641442

active_not_recruitingphase_2

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

NCT03827798

completedphase_3

A Single-patient Clinical Trial of MAS825 in a Patient With XIAP Deficiency

NCT06309823

View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials

NCT07203001Phase 2

A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease

Recruiting

NCT06097663Phase 2

A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)

Completed

NCT04641442Phase 2

Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations

Active Not Recruiting

NCT03827798Phase 2

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

Active Not Recruiting

NCT06309823Phase 3

A Single-patient Clinical Trial of MAS825 in a Patient With XIAP Deficiency

Completed

NCT04665154Phase 1

A First-in-human Study to Investigate the Safety, Tolerability and Pharmacokinetics of MAS825 in Healthy Volunteers

Completed

NCT04382651Phase 2

Study of Efficacy and Safety of MAS825 in Patients With COVID-19